Riskpilot← Back to searchSign inGet full accessEgetis Therapeutics Incentive AB
ABActiveOrg 5568848492Klara Norra Kyrkogata 26Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 20120 employees
Revenue 2024
SEK 0
EBITDA margin
—
-14% vs 2023
Equity ratio
95.6%
Financial strength
Net profit 2024
SEK -8K
-14% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | -14% |
| Net profit | SEK -8K | -14% |
| Total assets | SEK 295K | +0% |
| Equity | SEK 282K | -3% |
| Employees | 0 | — |
Legal name
Egetis Therapeutics Incentive AB
Org number
5568848492
Legal form
Aktiebolag
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
20 februari 2012
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall ha till föremål för sin verksamhet att bedriva hantering av incitamentsprogram för anställda i Egetis Therapeutics AB (publ) samt bedriva annan därmed förenlig verksamhet.
Address
Klara Norra Kyrkogata 26
Phone
+4686635700
Email
nicklas.westerholm@egetis.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 | −1 | −1 | −7 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 | −1 | −1 | −7 | −8 |
| Net financials | — | — | — | — | — |
| Profit before tax | −1 | −1 | −1 | −7 | −8 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 | −1 | −1 | −7 | −8 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 300 | 298 | 297 | 296 | 295 |
| Equity | 300 | 298 | 297 | 290 | 282 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 6 | 13 |
| Total debt | — | — | — | 6 | 13 |
EBITDA margin
-800000.0%
This company
15.8%
Market median
-5063391% vs market
20202024
Equity ratio
95.6%
This company
38.2%
Market median
+150% vs market
20202024
Return on equity
-2.8%
This company
18.4%
Market median
-115% vs market
20202024
Net profit margin
-800000.0%
This company
8.1%
Market median
-9876643% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JE Chief Auditor | Chief Auditor | 2024 |
| Former (3) | ||
AK Chief Auditor | Chief Auditor | 2022 – 2022 |
KJ Chief Auditor | Chief Auditor | 2021 – 2022 |
KL Chief Auditor | Chief Auditor | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Deputy Board Member | 2021 | |
| Former (2) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Egetis Therapeutics AB (publ)
Egetis Therapeutics Incentive AB Board members of Egetis Therapeutics Incentive AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Karin Siwertz | Chief Auditor | 0 companies |
| Kurt Jörgen Lövgren | Chief Auditor | 0 companies |
| Karl Leonard Daun | Chief Auditor | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Mats Peter Blom | Board of Directors | 0 companies |
| Per Thomas Lönngren | Board of Directors | 0 companies |
| Per Håkan Albin Åström | Board of Directors | 0 companies |
| Mervin Nicklas Mickael Westerholm | Deputy Board Member | 0 companies |